← Leaderboards
Gerardo Guillermo Mackenzie
University Of California At Davis
$2,170,462
Attributed
$3,934,346
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $803K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,934,346 · 7
By mechanism
R21$1,954,066 · 5
R01$1,822,280 · 1
R03$158,000 · 1
Top collaborators
- Mansoor M. Amiji7 shared
- James E Egan5 shared
- Edward J Kim5 shared
- Ruiwu Liu2 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Mansoor M. Amiji$9,305,730
- James E Egan$455,570
- Edward J Kim$988,864
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMalignant NeoplasmsChemotherapyMalignant Neoplasm Of PancreasDrug CombinationsPre-Clinical ModelEvaluationGrowthIn VitroPancreatic NeoplasmPharmaceutical PreparationsToxic EffectClinical TrialsDrug KineticsTreatment StrategyTumor GrowthAnimal ModelDiagnosisPancreatic Ductal AdenocarcinomaAreaGemcitabinePancreatic Cancer CellsSafetyAffect
Grant awards (18)
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$572,502
R01 · FY2025 · CA · contact PI
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$86,583
R01 · FY2025 · CA · contact PI
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$496,381
R01 · FY2024 · CA · contact PI
TGX-1214 - Combination strategy for the treatment of advanced pancreatic cancer$83,743
R01 · FY2024 · CA · contact PI
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$583,071
R01 · FY2023 · CA · contact PI
A novel small molecule targeting protein translation for pancreatic cancer treatment$219,912
R21 · FY2023 · CA · contact PI
A novel small molecule targeting protein translation for pancreatic cancer treatment$186,416
R21 · FY2022 · CA · contact PI
Phospholipase D1 and pancreatic cancer$403,688
R21 · FY2020 · CA · contact PI
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors$217,282
R21 · FY2018 · CA
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors$170,738
R21 · FY2017 · CA
Pancreatic cancer control by a novel combination treatment$171,825
R21 · FY2016 · CA · contact PI
Two phospho-compounds for pancreatic cancer prevention$163,280
R21 · FY2016 · CA · contact PI
A novel combination approach for pancreatic cancer prevention$62,800
R03 · FY2016 · CA · contact PI
A novel combination approach for pancreatic cancer prevention$16,200
R03 · FY2016 · CA · contact PI
Two phospho-compounds for pancreatic cancer prevention$8,545
R21 · FY2016 · CA · contact PI
Two phospho-compounds for pancreatic cancer prevention$206,190
R21 · FY2015 · CA · contact PI
Pancreatic cancer control by a novel combination treatment$206,190
R21 · FY2015 · CA · contact PI
A novel combination approach for pancreatic cancer prevention$79,000
R03 · FY2015 · CA · contact PI